Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World’s First Saliva-Based Exosomal Biomarker “miR-185” as Dual Diagnostic and Therapeutic Target for Oral Cancer
January 28, 2019 08:00 ET
|
Avalon GloboCare Corp.
Study Accepted as Poster Presentation at the 8th Annual Meeting of the International Society for Extracellular Vesicles (ISEV 2019) Publication of PCT Patent Application Covering a Method for...
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit
January 15, 2019 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that its President and Chief Executive...
Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy
January 03, 2019 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that the Company and its wholly owned...
Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern
December 19, 2018 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that it will ring The...
Avalon GloboCare Provides Third Quarter 2018 Business Update; Reports 30% Increase in Revenues
November 13, 2018 09:05 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a...
Avalon GloboCare Announces Listing on NASDAQ Capital Market
November 05, 2018 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced its common stock has...
Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey
October 15, 2018 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the grand opening of...
Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes
October 09, 2018 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that Weill Cornell...
Avalon GloboCare Commences Operation of its Core GMP Platform, Epicon Biotech, to Facilitate Clinical Development of Cellular Therapies
September 20, 2018 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has officially...
Avalon GloboCare Provides Second Quarter 2018 Business Update; Reports 32% Increase in Revenues
August 15, 2018 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a...